Nervous system neoplasm

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

This early-phase trial tests a vaccine made from small protein pieces (peptides) designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. The study includes 24 adults with newly diagnosed, untreated glioblastoma that has a specific genetic marker. …

This early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The mai…

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This phase III trial tests whether giving several small doses of radiation (fractionated radiosurgery) after removing a brain tumor is better than a single large dose. About 242 patients with cancer that spread to the brain will be randomly assigned to one of the two radiation pl…

This study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the dru…

This early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…

Researchers are testing whether natural killer (NK) cells from a universal donor can be safely given with standard chemotherapy drugs and an immune-targeting antibody to children and young adults with neuroblastoma that has returned or stopped responding. The NK cells are modifie…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This early-phase study tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 36 adults with specific tumor types (MGMT methylated or unmethylated) will receive differ…

This early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This early-phase trial tests a new approach for people with HER2-positive brain tumors that have come back or not responded to standard treatment. Researchers take the patient's own T cells, attach a special antibody (anti-HER2) to them, and inject these 'CAR T cells' directly in…

This study tests a new way to give proton radiation to children with low-grade glioma, a common brain tumor. The goal is to avoid the hippocampus, a brain area key for memory, to reduce long-term memory loss. About 74 children will receive this targeted radiation, and researchers…

This phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…

This study tests a drug called selumetinib in adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink these tumors or slow their growth. Participants take the drug twice daily and are monitored …

This phase 1 trial tests a peptide vaccine designed to target a specific mutation (H3K27M) found in certain aggressive brain tumors called diffuse midline gliomas. Fifteen newly diagnosed patients receive the vaccine along with the immunotherapy drug atezolizumab after standard r…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This trial compares a combination of two drugs (cediranib and olaparib) against a single drug (bevacizumab) in people whose glioblastoma has returned after prior treatment. The goal is to see if the combination can delay tumor growth better than the standard approach. Participant…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tests a nasal spray drug called NEO100 (perillyl alcohol) in people with aggressive brain tumors (grade III or IV gliomas) that have come back or worsened. The trial has two phases: first to find the safest dose, then to see if it helps patients live longer. About 49 p…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This trial is testing whether adding hydroxychloroquine to two targeted cancer drugs (dabrafenib and trametinib) can help children and young adults with certain brain tumors that have come back or not responded to treatment. The study includes patients with specific genetic chang…

This study tests a precise type of radiation called proton therapy for people with a non-cancerous brain tumor called vestibular schwannoma. The goal is to see if this treatment can preserve hearing and control tumor growth while reducing side effects. About 30 adults with useful…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests a combination of a vaccine targeting the CMV virus (PEP-CMV) and an immunotherapy drug (nivolumab) in children and young adults with certain aggressive brain tumors, including diffuse midline glioma and medulloblastoma. The goal is to see if this approach is safe…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …

This phase III trial tests whether giving focused radiation (stereotactic radiosurgery) before surgery is better than after surgery for people with 1 to 4 brain metastases. About 237 participants will be randomly assigned to one of the two sequences. The goal is to see which orde…

This phase 1 trial tests a radioactive drug called Lutathera in people with glioblastoma, an aggressive brain cancer. The study includes two groups: newly diagnosed patients receiving Lutathera with standard radiation and chemotherapy, and patients with recurrent glioblastoma rec…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This early study tests a combination approach for recurrent glioblastoma, an aggressive brain cancer. The treatment uses focused ultrasound (NaviFUS) to temporarily open the blood-brain barrier, allowing the drug Avastin (bevacizumab) to reach the tumor more effectively. Ten adul…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This phase 2 trial tests a combination of six drugs (TEDDI-R) in 48 adults with aggressive B-cell lymphoma that has spread to the central nervous system. The goal is to see if this mix can control the cancer better than current treatments. Participants receive the drugs in 21-day…

This early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…

This study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-stage trial tests a combination of three drugs—lenalidomide, dinutuximab, and isotretinoin—in children whose neuroblastoma has not responded to treatment or has come back. The main goal is to find the safest dose of lenalidomide when used with the other drugs. Research…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests whether adding niacin (vitamin B3) to standard treatment (radiation and chemotherapy) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. The trial has two phases: first, finding a safe dose of niacin, and second, checking if it improve…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This early-phase study is testing the safety and how the body handles a drug called tovorafenib in Japanese children, teens, and young adults with a type of brain tumor (low-grade glioma) that has a specific genetic change (BRAF alteration) and has come back or is growing. Six pa…

This study tests whether combining two drugs, DFMO and etoposide, can help children and young adults (up to age 30) whose neuroblastoma has come back or not responded to standard treatment. About 131 participants will receive the drug combination to see if it delays cancer growth…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This study tests an oral drug called DFMO in children and young adults with high-risk neuroblastoma who are currently in remission. The goal is to see if taking DFMO for two years can prevent the cancer from coming back. The trial involves 441 participants and focuses on safety a…

This phase 2 trial tests whether pembrolizumab, an immunotherapy drug, can help the immune system attack recurrent glioblastoma, an aggressive brain cancer that has come back. Researchers will give the drug to about 18 patients who need surgery for their tumor, and then study how…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) is safer and more effective than standard chemotherapy (lomustine) for people whose glioblastoma (a type of aggressive brain cancer) has returned after initial treatment. About 184 partic…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This study tests a drug called alisertib in children and young adults (up to age 22) with rare, aggressive tumors called atypical teratoid rhabdoid tumors (AT/RT) in the brain or malignant rhabdoid tumors (MRT) elsewhere in the body. For patients whose cancer has come back or not…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This phase 2 trial is testing whether a combination of two drugs, talazoparib and temozolomide, can shrink tumors in people with rare cancers that have spread. The study includes 14 participants with advanced rare solid tumors, such as pheochromocytoma or paraganglioma, who have …

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This phase 1 trial tests the safety and tolerability of an experimental drug called Fb-PMT in people with recurrent glioblastoma, an aggressive brain cancer. Fb-PMT targets multiple cancer signaling pathways and is designed to cross the blood-brain barrier to reach the tumor. Res…

This study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This pilot study is testing a two-step treatment for people whose gliomas (a type of brain tumor) have come back after standard therapy. First, doctors use a laser guided by MRI to destroy as much tumor as possible. Then, they give a short course of focused radiation. The main go…

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…

This early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This phase 2 trial compares two types of higher-dose radiation (IMRT or proton beam) plus the chemotherapy drug temozolomide against standard radiation plus temozolomide in 606 people with newly diagnosed glioblastoma. The goal is to see if the higher-dose approaches improve over…

This early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…

This study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…

This trial tests a type of engineered immune cell therapy called 19(T2)28z1xx CAR T cells in adults with B-cell cancers that have returned or not responded to treatment. The main goal is to find the highest dose that causes few or mild side effects. Researchers will also check wh…

This early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…

This early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …

This study follows 165 children who previously took dabrafenib and/or trametinib for certain brain tumors. Researchers want to see if these drugs are safe over the long term and how they affect growth. The children continue their treatment and are monitored for side effects and d…

This early-phase trial tests adding mycophenolate mofetil, a drug usually used to prevent organ rejection, to standard chemotherapy and radiation for glioblastoma. The goal is to find a safe dose and see if the combination can make tumor cells more sensitive to treatment. About 6…

This early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This early-phase trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy)—in patients whose glioblastoma has returned after standard treatment. The goal is to see if the combination is safe and can help control the cancer. …

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…

This study tests a personalized approach for children with non-high-risk neuroblastoma, where treatment is guided by the tumor's biology and how it responds over time. Some children may only need monitoring instead of immediate therapy, potentially avoiding harsh side effects. Th…

This phase 2 trial tests a combination of three drugs—pembrolizumab (immunotherapy), olaparib (a targeted therapy), and temozolomide (chemotherapy)—in people with recurrent glioblastoma, a type of brain tumor that has come back after initial treatment. The study will enroll 78 ad…

This study tests a higher dose of a precise type of radiation called proton therapy for people with aggressive meningiomas (brain tumors). The goal is to find a safe dose that can better control the tumor after surgery. The study includes 21 participants with either grade II or g…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This early-stage trial tests a new type of CAR T-cell therapy designed to target a protein called MMP2 found on glioblastoma cells. The treatment uses a scorpion toxin fragment (chlorotoxin) to help the immune cells find and attack the tumor. Nineteen patients with recurrent or p…

This phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …

This early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…

This early-stage study tests an experimental pill called CRN04894 in 18 adults with Cushing's syndrome caused by too much ACTH hormone. The drug works by blocking the receptor that ACTH acts on, aiming to lower cortisol levels and control the disease. The main goals are to check …

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants …

This early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…

This Phase I trial tests whether infusing specially trained immune cells, called TAA-T, can safely target and attack high-risk brain tumors in children and adults. The cells are made from the patient's own blood and are designed to recognize multiple tumor-related proteins, poten…

This study follows about 80-100 Chinese children aged 3-16 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. All participants take the drug selumetinib (Koselugo) and are monitored for 24 months to see how well it works and what side ef…

This trial is testing whether adding an experimental drug called XS005 to the standard chemotherapy regimen (Stupp) is safe and shows promise for people with glioblastoma, an aggressive brain tumor. The study involves 13 adults aged 18 to 70 who will receive XS005 infusions over …

This early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is …

This trial tests whether an experimental virus called C134 is safe when injected directly into the brain tumor in people with recurrent malignant glioma, including glioblastoma. Participants receive two doses of the virus during surgery to remove the tumor. The study focuses on s…

This trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…

This study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…

This early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering th…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This pilot study is testing a new, shortened chemotherapy regimen called N9 for children with high-risk neuroblastoma, a type of cancer. The regimen combines several chemotherapy drugs given in different cycles to see if it is safe and effective. The study includes children under…

This study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…

This study tests whether adding an experimental drug called NanO2 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. NanO2 is designed to deliver more oxygen to tumors, which may make radiation work better. About …

This trial is testing whether mebendazole, a drug commonly used to treat intestinal parasites, can help children with brain tumors called gliomas. The study combines mebendazole with standard chemotherapy drugs to see if it is safe and effective. It includes children and young ad…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This Phase 3 trial tests a new drug called belzupacap sarotalocan (AU-011) for people with small choroidal melanoma or suspicious spots in the eye. The drug is injected into the eye and activated by a laser to target cancer cells. The study compares it to a sham (fake) procedure …

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…

This trial tests the drug savolitinib in children and adults whose brain tumors (medulloblastoma, high-grade glioma, or DIPG) have come back or not responded to treatment. The drug works by blocking an enzyme that some tumor cells need to grow. The study aims to find the safest d…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…

This trial tests an experimental drug called DYP688 in people with metastatic uveal melanoma, a rare eye cancer that has spread, and other melanomas with specific genetic mutations. The study aims to find a safe dose and see whether the drug can shrink tumors. Participants receiv…

This study compares two radiation methods—proton beam and photon beam (IMRT)—in 120 people with slow-growing brain tumors (IDH-mutant gliomas). The goal is to see which better preserves memory and thinking over time. Participants are randomly assigned to one type of radiation and…

This expanded access program offers vorasidenib, an oral drug, to people aged 12 and older with IDH-mutated glioma who have had surgery. The drug targets specific genetic mutations in tumor cells. The goal is to see if it can help control the disease without immediate need for ra…

This phase 2 trial tests the drug pembrolizumab in 101 adults with cancer that has spread to the brain or spinal cord. The goal is to see if the drug can shrink or stabilize these tumors. Participants receive pembrolizumab along with standard imaging and sometimes radiation. The …

This study looks at how well the drug vorasidenib works and how safe it is for people with a slow-growing type of brain tumor called grade 2 astrocytoma or oligodendroglioma that has an IDH1 or IDH2 mutation. The study includes people aged 12 and older in China who are treated in…

This phase 3 trial tests whether cabergoline, a drug already used for hormone-producing pituitary tumors, can shrink or slow the growth of non-functioning pituitary adenomas (NFPAs). These tumors do not produce excess hormones, so current treatment is limited to surgery or radiat…

This early-phase trial tests whether adding high-dose vitamin C and an iron supplement (ferumoxytol) to standard radiation and chemotherapy can help adults with newly diagnosed glioblastoma, an aggressive brain tumor. The study includes 17 participants and focuses on finding a sa…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This trial tests whether giving a low-dose infusion of desmopressin (dDAVP) during surgery for complex brain tumors around the pituitary gland can prevent dangerously high sodium levels (hypernatremia) in the first 24 hours after surgery. High sodium can cause brain bleeding, sei…

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…

This study follows 100 people with vestibular schwannoma (a non-cancerous ear tumor) who previously received a gene therapy called AAVAnc80-antiVEGF. Researchers will monitor for late side effects and measure tumor size changes over time using MRI scans. The goal is to understand…

This study tests whether using highly focused radiation on each individual brain tumor, instead of radiating the whole brain, can control cancer spread while protecting memory and thinking. It enrolls people with small cell lung cancer who have 1 to 10 brain metastases. Researche…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery …

This study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This study tests a drug called mirdametinib in 114 adults and children with a genetic condition called NF1 that causes nerve tumors (plexiform neurofibromas) that cannot be removed by surgery and cause serious problems. The drug works by blocking a protein that helps tumors grow.…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This trial tests a long-acting injection of leuprolide acetate in children with central precocious puberty, a condition where puberty starts too early. The goal is to suppress puberty-related hormones, slowing or stopping early development. The study includes children aged 4 to 9…

This early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…

This pilot study tests an experimental device called Optune in people with recurrent atypical or anaplastic meningioma, a type of brain cancer that has come back after surgery or radiation. The device delivers electric fields to the tumor area to try to stop cancer cells from gro…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…

This study tests whether adding an experimental antibody called Hu3F8 to a standard chemotherapy regimen (irinotecan and temozolomide) plus a immune-boosting drug (GM-CSF) is safe and effective for children with high-risk neuroblastoma. The trial enrolls patients whose neuroblast…

This pilot study tests a new surgical technique called the anterolateral thigh myofascial fat composite flap (ALT-MF) for repairing tongue defects after cancer surgery in obese patients (BMI 30 or higher). Traditional flaps can be too bulky in obese patients, leading to problems …

This expanded access program provides tazemetostat, a drug that blocks a protein called EZH2, to adults with serious or life-threatening solid tumors that have lost the INI1 or SMARCA4 protein. Eligible patients must have tried other treatments without success and cannot join a f…

This study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…

This study tests whether a personalized, two-phase radiation therapy approach can better control glioblastoma, an aggressive brain cancer. The treatment adapts the radiation plan based on tumor changes during therapy, potentially targeting the tumor more precisely while sparing h…

This trial tests whether a new type of MRI, called MR fingerprinting, can better show where a glioblastoma (an aggressive brain tumor) has spread compared to standard MRI. The goal is to help surgeons remove more of the tumor safely. The study involves adults with suspected gliob…

This early-stage trial is testing a new type of cell therapy for children with neuroblastoma that has returned or is hard to treat. The therapy uses the patient's own immune cells, which are modified in the lab to recognize and attack a protein called PHOX2B found on neuroblastom…

This early-stage study is testing whether a specially prepared membrane made from donated human tissue can help heal chronic wounds, like diabetic foot ulcers and eye surface injuries. The membrane is sterilized with different doses of radiation to find the best balance between s…

This phase 2 trial tests whether giving chemotherapy directly into the eye (subconjunctival carboplatin) along with systemic topotecan can shrink advanced retinoblastoma tumors in children with disease in both eyes. The goal is to preserve the eye and vision, avoiding removal. Pa…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This trial tests a combination of donor immune cells (targeting a common virus) and the drug pembrolizumab (Keytruda) in 58 people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach can shrink tumors and help patients live longer. The study has two…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…

This phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, pl…

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a vaccine called PEP-CMV in 30 children and young adults (ages 3–35) whose medulloblastoma or malignant glioma has come back. The vaccine is designed to train the immune system to attack tumor cells that carry a common virus protein (CMV). Participant…

This early-phase study tests a combination of two drugs—D2C7-IT and atezolizumab—in adults with a recurrent, aggressive type of brain cancer called grade IV malignant glioma. The main goal is to see if the combination is safe and what side effects it may cause. About 18 participa…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them under control longer. It involves 46 adults with cancer that has spread to the brain. The goal is to improve tumor control without causing serious side e…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer has spread to lymph nodes and who have already had surgery or radiation. About 100 adults will receive either avelumab or a placebo every two we…

This early-phase trial is testing the immunotherapy drug nivolumab in children and young adults whose high-grade glioma has come back or is getting worse. Participants receive the drug before and after surgery to remove as much of the tumor as possible. The main goals are to chec…

This phase II trial tests two targeted drugs, vemurafenib and cobimetinib, in 24 people with a rare type of brain tumor called papillary craniopharyngioma that has a specific genetic mutation (BRAF V600E). The drugs work by blocking enzymes that help tumor cells grow. The main go…

This study tests a tumor vaccine combined with daily low-dose chemotherapy for children whose high-risk neuroblastoma has returned or not responded to standard treatment. The vaccine is designed to train the immune system to recognize and attack neuroblastoma cells, while the low…

This study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and w…

This study investigates whether combining ACT001 (an oral drug) with pembrolizumab (an immunotherapy) can help people with recurrent glioblastoma, an aggressive brain cancer. Participants take the drugs before surgery to remove their tumor, allowing researchers to analyze how the…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…

This study tests whether giving pregabalin before brain tumor surgery can safely reduce pressure inside the skull. One hundred adults will receive either pregabalin or a placebo before and on the morning of surgery. Researchers will measure pressure using a painless eye ultrasoun…

This study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if …

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This study tests whether adding focused radiation (stereotactic radiosurgery) to a combination of targeted drugs (binimetinib and encorafenib) and an immunotherapy (pembrolizumab) can better control melanoma that has spread to the brain. It includes 10 adults with a specific gene…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study tests a technique that delivers two cancer drugs, bevacizumab and carboplatin, directly into the brain's arteries for people with recurrent glioblastoma or anaplastic astrocytoma. The goal is to see if this method is safe and can slow tumor growth better than standard …

This early-phase trial tests whether delivering the cancer drug bevacizumab (Avastin) directly into the brain's arteries can safely treat vestibular schwannoma (acoustic neuroma), a non-cancerous tumor that can cause hearing loss. The study enrolls up to 30 adults with growing tu…

This phase 2 trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink tumors in people with metastatic uveal melanoma, a rare and aggressive eye cancer. Participants receive chemotherapy to prepare their immune system, then an infu…

This early-stage trial tests a new surgical approach for recurrent glioblastoma, an aggressive brain cancer. After standard tumor removal, surgeons place a piece of abdominal tissue (omentum) into the brain cavity to bypass the blood-brain barrier. The study involves 10 adults an…

This study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that lack the MTAP gene. The goal is to find the safest dose and see if it shrinks tumors. About 329 people will take part across multiple phases.

This trial looks at the best time to give radiotherapy for brain metastases that can be surgically removed. It compares giving radiation before surgery, during surgery, or after surgery. The goal is to see which timing best prevents the tumor from coming back. About 90 adults wit…

This study tests whether adding cabergoline to osilodrostat works better than osilodrostat alone for controlling Cushing's disease. About 50 adults with active Cushing's disease will receive either the combination or the single drug. The goal is to see if the combo can lower cort…

This phase 2 trial tests whether adding a dendritic cell vaccine and an immune-boosting drug (varlilumab) to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. About 43 participants will receive the vaccine plus temozolomide, with some also getti…

This early-stage trial tests a new approach for children and young adults with neuroblastoma that has come back or not responded to standard treatments. Doctors take a patient's own immune cells (T-cells), genetically modify them in the lab to recognize and attack a protein calle…

This early-phase trial tests whether a special type of immune cell (CAR T cell) that targets a protein found on glioblastoma cells can be safely given along with two immunotherapy drugs (nivolumab and ipilimumab). The study involves 20 adults with recurrent or treatment-resistant…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This early-phase trial tests a new treatment for glioblastoma, an aggressive brain cancer. After standard therapy (surgery, chemo, radiation), a radioactive antibody is injected into the brain cavity to target remaining tumor cells and delay recurrence. The study enrolls 15 adult…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This study planned to test a two-part experimental treatment for newly diagnosed glioblastoma, a fast-growing brain cancer. The treatment combined a modified virus (Toca 511) designed to enter tumor cells and an extended-release antifungal drug (Toca FC) that the virus helps turn…

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This study tests whether adding the targeted drug pazopanib to standard chemotherapy (temozolomide) can safely control glioblastoma, an aggressive brain cancer. About 51 adults who had surgery and chemoradiation will receive the combination. The main goal is to find the best dose…

This early-phase trial tests a combination of three treatments—radioactive iodine (131-I-MIBG), an immunotherapy drug (nivolumab), and an antibody (dinutuximab beta)—in children whose high-risk neuroblastoma has come back or not responded to standard therapy. The main goal is to …

This study tests whether adding the drug daratumumab to standard chemotherapy and radiation can help people with a newly diagnosed aggressive brain cancer called glioblastoma. About 16 participants will receive the combination treatment. The goal is to see if the new approach imp…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This phase 2 trial tests a higher radiation dose given over just 3 weeks for patients 65 and older with glioblastoma or grade 4 astrocytoma. Using a special MRI-guided machine (MR-Linac), doctors can adjust the radiation daily to target the tumor more precisely. The goal is to se…

This phase 2 trial tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain lymphoma (primary DLBCL of the CNS) that has relapsed or not responded to standard treatment. The goal is to see if the combination can shrink tumors and impro…

This early-stage trial tests a new treatment called GD2 CAR T cells in 12 children and teens (ages 1-16) with neuroblastoma that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them to better recognize and …

This study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…

This study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma has returned or worsened. The goal is to find the safest and most effective dose to control the tumor and extend survival. Participants must have confirmed glioblastoma and be in ad…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…

This early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…

This study tests whether giving higher doses of focused radiation (stereotactic radiosurgery) to brain tumors is safe and effective, without also radiating the whole brain. About 135 adults with certain types of cancer that have spread to the brain will receive escalating radiati…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…

This early-phase trial tests a new type of immune therapy for children with neuroblastoma that has come back or not responded to treatment. Researchers take a patient's own T cells, add new genes to help them recognize and kill neuroblastoma cells and survive longer, then infuse …

This phase 3 trial tests whether giving the chemotherapy drug temozolomide earlier and for a longer time can help adults with glioblastoma live longer. About 486 participants will receive either the standard treatment or an intensified version that starts chemo within two weeks o…

This study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…

This study tests the drug selumetinib in adults with neurofibromatosis type 1 (NF1) who have painful, inoperable nerve tumors called plexiform neurofibromas. About 145 participants will receive either selumetinib or a placebo to see if the drug can shrink the tumors and reduce pa…

This early-stage trial tests a combination of three drugs—sorafenib, cyclophosphamide, and topotecan—in children and young adults with neuroblastoma that has relapsed or not responded to treatment. The main goal is to find the highest safe dose of sorafenib when given with the tw…

This study tests a new painless nerve growth factor eye drop (CHF6467) in 36 children and young adults with optic pathway glioma, a brain tumor that often causes vision loss. The goal is to see if the drops can protect or improve vision without the pain side effects of standard n…

This early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…

This Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one c…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This early-phase trial tests a new type of cell therapy for children and young adults with solid tumors that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are trained in the lab to recognize and attack multiple cancer…

This early-phase study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in teens and young adults with a type of brain tumor called glioma that has an IDH mutation. The goal is to find the safest dose and see how well the combination works for both newly diagn…

This study tests a new RNA-lipid particle vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma or osteosarcoma that has spread to the lungs. The vaccine is made from the patient's own tumor material and aims to train the immune system to attack the c…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…

This study tests a drug called lanreotide in 10 people with advanced or metastatic paraganglioma or pheochromocytoma, rare tumors that release hormones. The goal is to see if lanreotide can slow tumor growth compared to before treatment. Participants receive injections every 4 we…

This study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This study is testing a radioactive drug called Lutathera in teenagers aged 12 to 17 who have rare tumors of the digestive system or adrenal glands. The goal is to see if the drug is safe and how much radiation reaches organs. Eleven teens are taking part, and researchers are wat…

This pilot study tests whether an energy-restricted ketogenic diet (ERKD) can help control glioblastoma, an aggressive brain cancer. Sixteen adults with newly diagnosed glioblastoma will follow the diet while receiving standard radiation and chemotherapy. The goal is to see if th…

This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (temozolomide chemotherapy and Tumor Treating Fields) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 40 adults with this aggressive brain …

This study reviews medical records of 36 adults with relapsed or refractory primary central nervous system lymphoma (PCNSL) who were treated with ibrutinib alone or with R-CHOP chemo. The goal is to see how many patients respond to treatment. PCNSL is a rare and aggressive brain …

This study compares the safety of routine telephone or video follow-ups versus in-person visits for patients with non-functioning pituitary tumors. Over two years, 812 participants will be randomly assigned to remote or in-person check-ups. The goal is to see if remote follow-up …

This early-stage trial tests a personalized cell therapy called IL13Rα2 CAR-T for people with recurrent grade 4 glioma, an aggressive brain cancer. The treatment involves collecting a patient's immune cells, engineering them to target a protein on tumor cells, and infusing them b…

This study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…

This phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study looks at whether giving chemotherapy (and sometimes radiation) after removing the eye can prevent retinoblastoma from coming back in children. About 195 children with advanced retinoblastoma in one eye took part. The goal is to see if this extra treatment reduces the c…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This early-phase study tests whether a new type of cell therapy, made from a patient's own immune cells that are genetically modified to resist chemotherapy, can be safely given alongside standard chemotherapy for newly diagnosed glioblastoma. About 22 adults with this aggressive…

This phase 2 study tests whether adding the antiviral drug valganciclovir to standard treatment (radiation and chemotherapy) can help people with glioblastoma live longer. The idea is that many glioblastomas carry a virus called CMV, which may make the cancer more aggressive. Abo…

This early-stage trial tests a new approach for children whose high-grade glioma has come back after standard treatments. It combines specially grown stem cells with an immunotherapy drug called nivolumab. The main goals are to see if the treatment is safe and possible to deliver…

This study tests whether the drug eflornithine, taken as a pill after immunotherapy, can help prevent high-risk neuroblastoma from coming back in children. Twenty children under 18 who have completed standard treatment will take eflornithine for maintenance. Researchers will trac…

This study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how man…

This study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…

This study tests whether adding olaparib, a drug that blocks DNA repair in cancer cells, to standard chemoradiation can improve survival for people with high-grade gliomas that cannot be fully removed by surgery. The trial has two phases: first, finding the safest dose of olapari…

This phase 2 trial tests different chemotherapy regimens in 133 children with retinoblastoma, a rare eye cancer. The goal is to shrink tumors and avoid removing the eye or using radiation. Treatments include intravenous and intra-arterial chemotherapy, sometimes combined with las…

This phase I/II trial tests a combination of immune cells (dendritic cells) and two immunotherapy drugs (ipilimumab and nivolumab) for people with recurrent glioblastoma, an aggressive brain cancer. The treatment is given directly into the tumor during surgery, followed by more d…

This study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, a fast-growing brain tumor. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…

This phase 3 trial tests whether giving a dose of radiation directly to the tumor site during surgery (intraoperative radiotherapy) can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer without their cancer growing. The study involves 314 …

This early-stage trial tests a single dose of M032, a genetically modified herpes simplex virus that produces IL-12, in 29 patients with recurrent or progressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma). The virus is infused directly into the tumor area…

This study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning pat…

This program gives certain glioblastoma patients access to SurVaxM, a drug that helps the immune system fight brain cancer. It is for patients who cannot join other trials or who have already benefited from SurVaxM in a previous study. The treatment involves four doses given two …

This early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injectio…

This study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus a chemotherapy drug (melphalan) given directly to the liver through a special procedure. It includes 83 adults with advanced uveal melanoma that has spread mainly to the liver. The goal is t…

This study tests whether adding a special radiation tile (GammaTile) during brain surgery, followed by standard chemotherapy and radiation, is safe and feasible for people with newly diagnosed glioblastoma. About 61 participants will receive the tile implant at the time of tumor …

This study tests whether a new type of PET scan (18F-MFBG) can detect neuroblastoma tumors as accurately as the current standard scan (123I-MIBG). About 84 children and adults with newly diagnosed, high-risk neuroblastoma will receive both scans to compare results. If the new sca…

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

This study will compare two types of PET scans (using different radioactive tracers) in 6 adults with suspected meningioma who are scheduled for surgery. Each person will get both scans at least 24 hours apart. The goal is to see which tracer gives clearer images of the tumor, wh…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial explores whether focused ultrasound can enhance the release of tumor DNA into the blood and spinal fluid, potentially making liquid biopsies a more reliable way to diagnose brain tumors. Researchers will use MRI-guided focused ultrasound to partially ablate the tumor i…

This study tests a new imaging agent called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and suspected recurrent brain tumors will receive o…

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This phase 2 trial tests whether a fluorescent dye called fluorescein can help surgeons identify brain tumor tissue during an operation. About 30 adults with suspected glioma will receive the dye before surgery, and the surgeon will look for glowing areas through a special micros…

This study tests whether a special type of MRI scan can tell the difference between actual tumor growth and harmless treatment-related changes in people who have had surgery for a type of brain cancer called glioma. After treatment, it's often hard to know if a new spot on a scan…

This study compares a new, non-invasive PET-MRI scan to the standard invasive test (IPSS) for finding pituitary tumors in people with Cushing's disease. About 43 adults with confirmed Cushing's will get both tests to see which is more accurate. The goal is to make diagnosis safer…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This early study will test whether weak electrical currents applied to the head can help diagnose balance disorders like vestibular schwannoma and vestibular neuritis. Researchers will measure how 30 people with these conditions sway or move in response to the stimulation. The go…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This program gave patients with glioma (a type of brain tumor) access to a special imaging agent called 18F-FET. It was used with PET scans to help doctors tell the difference between actual tumor growth and changes caused by previous treatments. The goal was to improve treatment…

This study compares a new ultra-high resolution PET/CT scanner, the NeuroEXPLORER, with standard clinical PET/CT scanners for imaging the head and neck. Researchers aim to see if the new device provides more detailed images to improve diagnosis of conditions like dementia, Parkin…

This study looks at whether a liquid biopsy (a simple test that checks for cancer DNA in spinal fluid) can better detect and monitor brain involvement in people with high-risk B-cell non-Hodgkin lymphoma. Researchers will compare this new method to standard tests in 64 newly diag…

This study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can …

This study tests a special ultrasound technique called Superb Microvascular Imaging (SMI) to see blood flow inside eye tumors. The goal is to help doctors tell benign from malignant tumors more accurately, especially when standard tests are unclear. Twenty-two adults with untreat…

This study aims to see if a simple, inexpensive saliva test can accurately diagnose Cushing's syndrome, a condition where the body makes too much cortisol. Researchers will compare two automated saliva test methods in 380 adults who are already being checked for the condition. Th…

This study compares two different doses of radiation aimed at the head (prophylactic cranial irradiation) to see which is better at preventing brain metastases in people with small cell lung cancer. Participants had their lung cancer diagnosed within the past year and have alread…

This study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…

This study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study compares two radiation treatments for people whose non-melanoma cancer has spread to the brain with 4 to 15 tumors. One method, stereotactic radiosurgery, delivers a high dose only to the tumors, while the other treats the whole brain. The goal is to see which better c…

This study tests whether a single large dose of spine radiosurgery works better than three smaller doses for people whose spinal tumors have come back after previous radiation. About 80 adults with solid tumors that spread to the spine will be randomly assigned to one of the two …

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This study compares three different drugs (dexmedetomidine, fentanyl, and magnesium sulphate) used alongside propofol anesthesia for brain surgery. The goal is to see which combination reduces the amount of propofol needed and improves patient outcomes. 108 adults undergoing elec…

This trial tests whether applying two topical lotions, clindamycin and triamcinolone, can prevent skin irritation caused by Tumor Treating Fields (TTFields) in people with glioblastoma. Participants will use the lotions at each array change, and researchers will track how many de…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study tests a modified whole brain radiation technique that avoids a specific area of the brain called the corpus callosum genu, which is important for memory and thinking. The goal is to see if this approach helps preserve cognitive function in people with brain metastases …

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study explores whether a supervised, circuit-based resistance training program can help glioblastoma patients maintain muscle mass and perform daily tasks more easily. Researchers will enroll 24 adults with glioblastoma who are currently on treatment. Participants will exerc…

This trial planned to compare a second round of whole brain radiotherapy plus supportive care against supportive care alone for people with brain metastases that returned after initial treatment. It was designed for patients who could not have surgery or precise radiation. Howeve…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at how precise radiation (stereotactic radiosurgery) affects memory and thinking in people with 6 or more brain tumors that have spread from other cancers. About 80 adults will take part to find the safest radiation dose and measure any decline in memory over 4 m…

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…

This study explores whether an Apple Watch can track walking, heart rate, breathing, and sleep in people with glioblastoma, a serious brain cancer. The goal is to see if the watch can detect symptom changes before they become serious, like seizures or blood clots. Twenty-five pat…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study follows 110 people with brain metastases who are receiving either focused or whole-brain radiation. Researchers use advanced MRI scans and memory tests before treatment and for two years after to see if the scans can predict thinking and memory problems. The goal is to…

This study aims to find blood-based biomarkers that signal the presence and size of plexiform neurofibromas in people with Neurofibromatosis type 1 (NF1). Researchers will collect blood samples and use whole-body MRI to compare biomarker levels in 200 participants with different …

This study tracks a substance called 2-HG in the brains of people with a type of brain cancer (glioma) that has specific gene changes. By using special MRI scans over time, researchers hope to learn how and when these tumors become more aggressive. About 42 adults will have regul…

This study looks at children and teens who survived retinoblastoma in one eye. Researchers want to see if those who had chemotherapy injected into the eye artery have a different quality of life than those who had the eye removed. Participants and their parents will fill out surv…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This 5-year study follows 250 people with von Hippel-Lindau disease who have brain or spinal cord tumors. Researchers use regular MRI scans and blood tests to see how fast tumors grow and what factors like hormones might affect growth. The goal is to better understand which tumor…

This study is testing whether a blood test (liquid biopsy) can detect a rare but serious nerve tumor called MPNST earlier than current methods in adults with Neurofibromatosis Type 1 (NF1). Researchers will compare the timing of tumor detection by the blood test versus standard i…

This study tests whether a substance called 5-ALA, already used during brain surgery to make tumor cells glow, can also be detected in blood or urine. Researchers hope this 'liquid biopsy' could help diagnose and monitor glioblastoma, the most common and deadly brain tumor, witho…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study looks at epigenetic changes in meningioma tumors and blood samples to find markers that could predict if the tumor will come back after surgery. Researchers will analyze tissue from past patients and collect blood from new patients. The goal is to improve personalized …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study monitors the safety of selumetinib in children aged 3 to 18 with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas. Researchers will track potential side effects on the heart, bones, muscles, liver, eyes, and puberty. The goal is to better un…

This study looks at how parents make treatment decisions when their child has relapsed neuroblastoma, a type of cancer. Researchers want to understand if parents' choices match their true preferences, and whether they feel regret or burden over time. By following 96 parents, the …

This study investigates whether the emotional distress of parents—such as depression, anxiety, or trauma—affects how well children with recurrent medulloblastoma follow their treatment plans. Researchers will follow 450 parent-child pairs across four hospitals, measuring parental…

This study is a long-term follow-up for 100 people who completed a previous trial of bel-sar, an experimental treatment for early choroidal melanoma (a type of eye cancer). Participants will not receive any new treatment but will be monitored for about 5 more years to check for s…

This study follows 800 adults who have had their first ischemic stroke in Central Norway for up to 10 years. Researchers will track how physical activity, medication use, and control of blood pressure and cholesterol affect the risk of death, another stroke, or severe disability.…

This study follows people diagnosed with uveal melanoma, a rare eye cancer, over time to document the disease's natural course. Researchers will collect data on how the cancer progresses, including survival rates and whether it spreads. The goal is to build a detailed registry th…

This study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study evaluates a sensor-based version of the Timed Up and Go test (QTUG) for measuring balance and predicting fall risk in older adults with dizziness (vestibulopathy). Researchers will compare QTUG results with other balance tests, track whether a six-month vestibular reha…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study follows children and young adults (up to age 35) with brain or skull base tumors who are scheduled to receive radiation therapy to the brain. Researchers use brain scans to track changes in brain structure and volume over time. They also measure thinking skills, hormon…

This study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…

This study looks at whether a large database of patient health records (Truveta) can be used as a control group for a glioblastoma drug called BPM31510. Glioblastoma is a fast-growing brain tumor, and it is hard to run traditional placebo-controlled trials because the disease is …

This study was designed to look back at the health of people with Cushing's disease in Western France between 1990 and 2015. The goal was to find out how many patients went into remission and how many had their disease come back after their first surgery. However, the study was w…

This Phase 2 trial tests whether dichloroacetate (DCA), a drug that affects cell energy use, can alter tumor metabolism in people with recurrent glioblastoma. Forty patients scheduled for surgery will either receive DCA or no drug for one week before their operation. Researchers …

This study investigates how the brain processes speech sounds to understand language. Researchers will record brain activity from people with epilepsy or brain tumors who already have electrodes implanted for medical reasons. Participants listen to short speech sounds while their…

This study investigates whether a simple blood test can help diagnose and monitor low-grade gliomas, a type of slow-growing brain tumor. Researchers will collect blood samples from 50 patients undergoing brain surgery to look for circulating tumor cells and other markers. The goa…

This study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study tests whether using an app for patients to report symptoms can guide when to do MRI scans, instead of following a fixed schedule. It involves 20 adults with newly diagnosed glioblastoma. The goal is to see if this approach is feasible and acceptable, not yet to prove i…

This study collects multiple samples from different parts of a glioblastoma tumor during surgery. Researchers will analyze the samples to learn how genetic changes vary within a single tumor. The goal is to improve future diagnosis and treatment of brain tumors. The study involve…

This study looks at whether simple blood tests can help doctors understand how glioblastoma, a serious brain cancer, changes over time. About 100 newly diagnosed patients will give blood samples before and after standard radiation and chemotherapy. The goal is to see if DNA from …

This study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…

This registry follows 63 patients with choroidal melanoma or early eye lesions who were treated with the experimental drug bel-sar in earlier studies. The goal is to monitor long-term safety, side effects, and any spread of the disease over time. Participants are not receiving ne…

This early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…

This study follows 400 patients for two years after they have endoscopic endonasal skull base surgery (surgery through the nose to reach the base of the skull). The goal is to measure their quality of life and nose function using standard questionnaires. It does not test a new tr…

This study follows 75 adults with benign or slow-growing brain tumors who are receiving partial brain radiation. Researchers will use memory tests and MRI scans before treatment and at 6 and 12 months after to see how radiation affects thinking and memory. The goal is to identify…

This early-phase trial is testing whether ketoconazole, a drug normally used for fungal infections, can get into brain tumors (gliomas) in enough amounts to possibly slow their growth. About 80 adults with different grades of glioma will take low doses of the drug before their sc…

This study tests a camera that uses different colors of light to tell the difference between low-grade brain tumor tissue and normal brain tissue during surgery. Ten adults with suspected low-grade glioma will have the camera used during their tumor removal operation. The goal is…

This study is a registry that collects medical records, quality-of-life questionnaires, and tissue samples from 900 people with spine tumors or other spine disorders. The goal is to learn more about these conditions to guide better treatment in the future. Participants must be be…

This study tracks 80 patients with brain tumors (metastases or meningiomas) who receive stereotactic radiosurgery. Researchers use memory tests and quality-of-life questionnaires before treatment and every 3 months for a year to see if and how brain function changes. By comparing…

This study tests a new type of cochlear implant that uses light instead of electricity to stimulate the hearing nerve. Researchers hope light can target smaller nerve groups, leading to clearer sound. The trial involves 30 adults who are already having ear surgery for tumor remov…

This study looks at two different blood pressure goals for adults who just had brain tumor surgery. Half the patients will have a target of less than 160 mmHg, the other half less than 140 mmHg. Researchers want to see which group leaves the hospital sooner, without more bleeding…

This study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatme…

This long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…

This study looks at three ways surgeons place screws in the spine during surgery: using a robot, using a navigation system, or doing it by hand. The goal is to see which method leads to fewer screws needing to be fixed in a second surgery within the first year. About 932 adults w…

This study looks back at 50 people who had surgery for rare spinal cord tumors between 2022 and 2024. Researchers want to see how the surgery changed their nerve function, movement, and daily life. They also track complications like infections or bleeding. The goal is to learn wh…

This small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…

This study is observing 328 adults who receive a Neuro-Patch during brain or spine surgery to repair the protective lining around the brain or spinal cord. Researchers are tracking complications and how easy the patch is for surgeons to use. The goal is to gather real-world data …

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study is not testing a new treatment. Instead, researchers are reviewing medical records from 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how well past chemotherapy and targeted therapies worked. The goal is to learn which treatments are lin…

This study aims to develop a liquid biopsy—a blood test—to detect tumor DNA in patients with high-grade gliomas, an aggressive type of brain cancer. Researchers will collect blood samples from 70 patients before and after standard radiotherapy to see if they can measure tumor cha…

This observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumor…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This study is a registry that gathers detailed information from about 960 adults with metastatic spine tumors (cancer that has spread to the spine from elsewhere). Researchers collect data on patients' health, treatments, symptoms, and quality of life over time. The goal is to be…

This study is part of a larger trial testing an oxygen-boosting drug called NanO2 in people with glioblastoma, a serious brain cancer. Researchers will analyze blood samples from 40 patients to find markers that show how low oxygen levels in the tumor affect the disease. They als…

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study looks at patients with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers will review different treatment strategies used at two hospitals to see which leads to longer survival without the disease getting worse. The goal is t…

This study tracks 42 people with ocular melanoma who received radiation therapy via eye plaque brachytherapy. Researchers want to see if using lower radiation doses can still keep the cancer from coming back while reducing harmful side effects. The goal is to find the safest effe…

This study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study looks at how aggressive brain tumors (gliomas) suppress the immune system. Researchers will use special MRI and PET scans to track immune cells and iron levels in the tumor. The goal is to find better ways to measure immune suppression, which could help develop new tre…

This study looks at how brain tumors change the way different parts of the brain connect and communicate. Researchers will use brain scans and electrical recordings from 30 adults scheduled for tumor removal surgery. The goal is to better understand brain plasticity and improve f…

This study looks at how cancer treatment and multiple rounds of anesthesia affect thinking skills, emotions, and quality of life in people who survived retinoblastoma (a rare eye cancer) or were at risk for it. Researchers will test memory, attention, and other brain functions in…

This study was designed to see if a special MRI technique could help surgeons map important brain pathways in people with malignant brain tumors. It was withdrawn before any participants were enrolled, so no data or results were collected. The goal was to compare the MRI findings…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This study collects blood and bone marrow samples from 40 adults with newly diagnosed glioblastoma to track changes in immune cells over time. Researchers aim to understand how the immune system responds to the tumor and standard treatments. The goal is to gather foundational dat…

This study follows 500 people with neurofibromatosis type 1 (NF1) to see how their skin tumors (called cutaneous neurofibromas) grow and change over time. Researchers use 3D whole-body photography to track tumor number and size each year. The goal is to better understand these tu…

This study tests whether adding a weekly check-in with a radiology technician (called a MERM) to standard doctor visits can better detect side effects in brain tumor patients receiving proton therapy. About 92 adults with brain or upper airway tumors will be randomly assigned to …

This study looks at whether yearly MRI scans can find new head and neck or brain cancers early in people who had hereditary retinoblastoma and were treated with radiation. Researchers will follow 88 participants for 10 years to see if early detection leads to better surgery outco…

This study compares two anesthetic drugs, fentanyl and ketamine, to see which one better helps surgeons find seizure-causing brain tissue during epilepsy surgery in children. Eighty-eight children aged 2-18 with brain tumors and epilepsy will receive one of the drugs during surge…

This study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…